Clinical Trial Update: Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol evaluating AZD9291 (osimertinib) as a targeted treatment for cancers with EGFR genetic changes; the trial is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Lymphoma
• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-18